The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Characterizing non-small cell lung cancer driven by mutations in ARAF and CRAF family members.
 
Tamio Okimoto
No Relationships to Disclose
 
Joseph Amann
No Relationships to Disclose
 
Andrew Elliott
Employment - Caris Life Sciences
 
Stephen V. Liu
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Candel Therapeutics; Catalyst Pharmaceuticals; Daiichi Sankyo/UCB Japan; Eisai; Elevation Oncology; Genentech; Gilead Sciences; Guardant Health; Janssen Oncology; Jazz Pharmaceuticals; Merus; MSD Oncology; Novartis; Regeneron; Sanofi; Takeda; Turning Point Therapeutics
Research Funding - Alkermes (Inst); Elevation Oncology (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); Merck (Inst); Merus (Inst); Nuvalent, Inc. (Inst); RAPT Therapeutics (Inst); Turning Point Therapeutics (Inst)
Travel, Accommodations, Expenses - Caris Life Sciences
 
Patrick C. Ma
Honoraria - AstraZeneca
Consulting or Advisory Role - AstraZeneca; Caris Life Sciences
Research Funding - Abbvie (Inst); Apollomics (Inst); AstraZeneca (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Elevation Oncology (Inst); Genmab (Inst); Merck (Inst); Mirati Therapeutics (Inst); OncoC4 (Inst); Roche/Genentech (Inst)
 
Ari M. Vanderwalde
Employment - Caris Life Sciences
Consulting or Advisory Role - Bristol-Myers Squibb; Caris Life Sciences; Compugen; Concerto HealthAI; Elsevier; Inivata
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Caris Life Sciences (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Immunomedics/Gilead (Inst); Lilly (Inst); Merck (Inst); Millennium (Inst); Replimune (Inst)
 
Milan Radovich
Employment - Caris Life Sciences
Leadership - Caris Life Sciences
Stock and Other Ownership Interests - LifeOmic
Research Funding - Lilly (Inst)
Patents, Royalties, Other Intellectual Property - Combination therapy for the treatment of TNBC with a PI3K pathway inhibitor that targets PI3KDelta and PI3KGamma (Inst)
Travel, Accommodations, Expenses - Caris Life Sciences
 
George W. Sledge
Leadership - Syndax; Tessa Therapeutics
Stock and Other Ownership Interests - Pionyr; Syndax; Tessa Therapeutics
Consulting or Advisory Role - AstraZeneca; Caris Life Sciences; G1 Therapeutics; GRAIL; Synaffix; Syndax; Verseau Therapeutics
Research Funding - Genentech/Roche (Inst); Pfizer (Inst); QED Therapeutics (Inst)
Travel, Accommodations, Expenses - Caris Life Sciences; Tessa Therapeutics; Verseau Therapeutics
 
Vincenzo Coppola
No Relationships to Disclose
 
David Paul Carbone
Employment - James Cancer Center
Honoraria - AstraZeneca; Bristol-Myers Squibb-Ono Pharmaceutical
Consulting or Advisory Role - Abbvie; Arcus Biosciences; AstraZeneca; Bristol-Myers Squibb; Curio Science; EMD Serono; Genentech/Roche; GlaxoSmithKline; Intellisphere; InThought; Iovance Biotherapeutics; Janssen; Jazz Pharmaceuticals; Johnson & Johnson/Janssen; Lilly; Merck; Merck KGaA; Mirati Therapeutics; MSD Oncology; NCCN/AstraZeneca; Novartis; OncLive/MJH Life Sciences; Pfizer; PPD; Regeneron; Roche; Sanofi